Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
9Customers
3Debt Items
13Related Chains
Source-Backed Evidence Depth
ADMA Biologics, Inc. (ADMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
2Distinct source URLs
8High confidence
0.762Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
ADMA Biologics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
GRIFOLS-WORLDWIDE-OPERATIONS-LIMITED
GRIFOLS-WORLDWIDE-OPERATIONS-LIMITED
92%
Pursuant to the A&R Grifols Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually to be used in the manufacture of ASCENIV.
GENESISBPS
GENESISBPS
90%
The Company purchased source plasma from GenesisBPS in the amount of approximately $ 34,000.
tive tax rates. We may be subject to audits of our income, sales, and other transaction taxes by U.S. federal, state, and local taxing authorities. Outcomes from these audits could have a material ef…
Reciprocal relationship from STT-PG graph: Reciprocal relationship from ADMA graph: Reciprocal relationship from STT-PG graph: Reciprocal relationship from ADMA graph: tive tax rates. We may be subje…
Reciprocal relationship from KMDA graph: Reciprocal relationship from ADMA graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from ADMA graph: Reciprocal relationship from KMDA g…
ADMA Biologics, Inc. Customers
Ticker
Name
Confidence
Evidence
BIOTEST-AG
BIOTEST-AG
85%
he out-licensing of ASCENIV to Biotest AG (“Biotest”) in 2012 to market and sell this product in Europe and certain countries in Northern Africa and the Middle East. Biotest has provided the Company …
PRIORITY-HEALTHCARE-DISTRIBUTION-INC
PRIORITY-HEALTHCARE-DISTRIBUTION-INC
85%
ioCare”) and Priority Healthcare Distribution, Inc. d/b/a CuraScript SD Specialty Distribution (“Curascript”), represented an aggregate of approximately 71% and 64%, respectively, of our consolidated…
Reciprocal relationship from STT-PG graph: Reciprocal relationship from ADMA graph: Reciprocal relationship from STT-PG graph: Reciprocal relationship from ADMA graph: Reciprocal relationship from ST…
o the manufacture and marketing of our products and product candidates may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from participation in ap…
ADMA-BIOCENTERS-GEORGIA-INC
ADMA-BIOCENTERS-GEORGIA-INC
62%
h equivalents - end of period $ 138,153 $ 71,625 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Index ADMA BIOLOGICS, INC. AND SUBSIDIARIES NOTES …
ADMA-BIOMANUFACTURING-LLC
ADMA-BIOMANUFACTURING-LLC
62%
h equivalents - end of period $ 138,153 $ 71,625 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Index ADMA BIOLOGICS, INC. AND SUBSIDIARIES NOTES …
BLACKROCK-INC-STATE-STREET-CORPORATION-INVESCO-L
BLACKROCK-INC-STATE-STREET-CORPORATION-INVESCO-L
62%
o the manufacture and marketing of our products and product candidates may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from participation in ap…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
o the manufacture and marketing of our products and product candidates may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from participation in ap…
DISPOSAL-GROUP
DISPOSAL-GROUP
62%
ct of which is currently being evaluated. 3. INVENTORIES The following table provides the components of inventories: March 31, 2026 December 31, 2025 (In thousands) Raw materials $ 89,281 $ 96,612 Wo…
ADMA Biologics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ADMA-DEBT-7511
Warrants outstanding: 966554
90%
xbrl warrant detail from xbrl 2025-12-31.
ADMA-DEBT
Debt stack $196.6M
90%
Market cache reports total debt of $196.6M.
ADMA-DEBT-7512
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2012-12-31.
ADMA Biologics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ADMA Biologics, Inc..
ADMA Biologics, Inc. Ownership
Holder
Name
Confidence
Evidence
ADMA-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 360 tracked holders.
ADMA Biologics, Inc. Extended Supply Chain Network
